Biotech News

Arvinas Employees Give Back During Company-wide Impact Day

Arvinas, Inc. (ARVN)Arvinas, Inc.2026-05-18 14:30 ESTCompany update

NEW HAVEN, Conn., May 18, 2026 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to create a new class of drugs based on targeted protein degradation, today announced that employees across Connecticut, in the Greater Boston area, and around the

Arvinas, Inc.

Arvinas is a biopharmaceutical company focused on advancing a pipeline of therapeutic programs. Investors usually track how clinical data, regulatory milestones, and launch execution change the story over time.

Recent company news

ARVNArvinas, Inc.2026-06-04 12:00 EST

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

ARVNArvinas, Inc.2026-05-29 20:01 EST

Arvinas and Pfizer Enter into a Transaction with Rigel Pharmaceuticals for the Exclusive Global Rights of VEPPANU (vepdegestrant)

Stock data

Close: 10.78 USD
Market cap: 695.5M USD
Exchange: NASDAQ
Sector: Biopharma
Location: United States

Arvinas Employees Give Back During Company-wide Impact Day

Related news

Arvinas Announces Positive Phase 1 Data for ARV-102 Showing Greater Than 50% LRRK2 Degradation in the CSF of Patients with Parkinson’s Disease Treated for 28 Days

Arvinas to Present Phase 1 Data for ARV-102, a PROTAC LRRK2 Degrader, in Oral Session at the 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders

Arvinas, Inc.

Recent company news

Arvinas Joins The Michael J. Fox Foundation’s LITE and PPMI Programs to Advance New Therapies Targeting LRRK2 for Parkinson’s Disease

Arvinas to Present at Jefferies Global Healthcare Conference